Sanofi (NASDAQ:SNY) Shares Purchased by HighTower Advisors LLC

HighTower Advisors LLC lifted its holdings in Sanofi (NASDAQ:SNYFree Report) by 8.8% in the 3rd quarter, Holdings Channel reports. The firm owned 316,925 shares of the company’s stock after buying an additional 25,641 shares during the quarter. HighTower Advisors LLC’s holdings in Sanofi were worth $16,991,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Arrowstreet Capital Limited Partnership lifted its position in Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after acquiring an additional 2,468,271 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Sanofi by 20.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 7,556,281 shares of the company’s stock worth $407,284,000 after acquiring an additional 1,282,350 shares during the last quarter. Morgan Stanley lifted its position in Sanofi by 19.3% during the 4th quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock worth $374,513,000 after acquiring an additional 1,251,199 shares during the last quarter. Perceptive Advisors LLC acquired a new position in Sanofi during the 1st quarter worth $41,800,000. Finally, Goldman Sachs Group Inc. lifted its position in Sanofi by 24.2% during the 2nd quarter. Goldman Sachs Group Inc. now owns 2,643,615 shares of the company’s stock worth $132,260,000 after acquiring an additional 515,245 shares during the last quarter. Institutional investors and hedge funds own 10.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SNY. Morgan Stanley began coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. JPMorgan Chase & Co. lowered shares of Sanofi from an “overweight” rating to a “neutral” rating in a research report on Tuesday, December 5th. StockNews.com raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, January 9th. Finally, Stifel Nicolaus lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Sanofi has an average rating of “Hold” and a consensus target price of $57.50.

Read Our Latest Report on Sanofi

Sanofi Stock Performance

NASDAQ SNY opened at $46.50 on Monday. The stock has a market cap of $117.63 billion, a P/E ratio of 19.70, a PEG ratio of 1.70 and a beta of 0.63. The company’s 50-day simple moving average is $49.26 and its 200 day simple moving average is $50.60. Sanofi has a twelve month low of $42.63 and a twelve month high of $57.82. The company has a quick ratio of 0.38, a current ratio of 1.28 and a debt-to-equity ratio of 0.19.

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Recommended Stories

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.